Zenas BioPharma (ZBIO) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
11 May, 2026Opening remarks and agenda
The meeting was called to order at 8:00 A.M. Eastern Time on May 11, 2026, marking the second Annual Meeting as a public company.
The Chief Legal Officer and Corporate Secretary was introduced to assist with procedural matters.
Independent Auditors from Ernst & Young LLP and the Inspector of Elections were present to oversee proceedings.
Stockholders could access the agenda and submit questions via the web portal.
Board and executive committee updates
Two Class II Directors, James Boylan and Patrick Enright, were nominated for election to serve until the 2029 Annual Meeting.
Shareholder proposals
No additional proposals were introduced by stockholders as none were submitted in accordance with bylaws.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Zenas BioPharma
- Obexelimab cut IgG4-RD flare risk by 56% in Phase 3, meeting all endpoints with strong safety.ZBIO
Study Result9 Jul 2026 - Year-end phase III IgG4-RD results and strong MS data mark key inflection points.ZBIO
Jefferies London Healthcare Conference 20259 Jul 2026 - Obexelimab's clinical programs in IgG4-RD, MS, and lupus advance with key data readouts expected by 2025.ZBIO
Citi's 2024 Global Healthcare Conference8 Jul 2026 - Obexelimab nears launch for IgG4-RD, with a robust neuro pipeline advancing toward key milestones.ZBIO
7th Annual HCW Neuro Perspectives Hybrid Conference15 Jun 2026 - Advancing best-in-class therapies for autoimmune diseases with strong late-stage clinical momentum.ZBIO
Corporate presentation3 Jun 2026 - Obexelimab and orelabrutinib advance toward 2027 launches, targeting multi-billion dollar markets.ZBIO
Corporate presentation13 May 2026 - Q1 2026 net loss rose to $81M; positive Phase 3 data and financing extend runway into 2029.ZBIO
Q1 202613 May 2026 - Vote on two director nominees and auditor ratification at the May 2026 virtual meeting.ZBIO
Proxy Filing16 Mar 2026 - 2026 meeting to elect directors, ratify auditor, and highlight governance, compensation, and ESG.ZBIO
Proxy Filing16 Mar 2026